Quantcast
Last updated on April 16, 2014 at 11:16 EDT

Latest Adalimumab Stories

2012-06-05 18:22:56

BERLIN, June 6, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from two long-term, open-label studies, which evaluated the results of HUMIRA® (adalimumab) treatment for up to 10 years in patients with long-standing, moderate-to-severe rheumatoid arthritis (RA). These 10-year HUMIRA studies, DE019 and DE020, are among the longest, open-label trials in RA. Results presented at the European League Against Rheumatism (EULAR) 2012 Congress in Berlin, Germany, include...

2012-06-05 18:22:52

BERLIN, June 6, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from the open-label extension of the Phase 3 ABILITY-1 investigational study of HUMIRA® (adalimumab), which assessed the improvement in signs and symptoms of disease for patients with active axial spondyloarthritis (axSpA) who have no X-ray evidence of structural damage. Results were presented at the European League Against Rheumatism (EULAR) 2012 Congress in Berlin, Germany. ABILITY-1 is the first large,...

2012-06-01 08:59:44

Education is key to success; functional disability negatively impacts job performance As children with juvenile idiopathic arthritis (JIA) grow into adulthood, disability due to disease may adversely affect their ability to achieve educational success. Findings published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), suggest that functional disability impacts educational attainment, which is key to successful employment in adulthood. Arthritis is...

2012-05-31 23:00:20

"Ankylosing spondylitis is now being treated with regenerative medicine at he center for regenerative medicine." according to A.J. Farshchian MD an orthopedic regenerative practitioner at the center for regenerative medicine. Miami, Florida (PRWEB) May 30, 2012 "Ankylosing spondylitis is now being treated with regenerative medicine at he center for regenerative medicine." according to A.J. Farshchian MD an orthopedic regenerative practitioner at the center for regenerative medicine....

2012-05-31 14:23:24

LA JOLLA, Calif., May 31, 2012 /PRNewswire/ -- Scripps Research Institute Professor Richard A. Lerner, MD, has won a prestigious international honor, the Prince of Asturias Award for Scientific and Technical Research, according to an announcement made today by the Prince of Asturias Foundation. Lerner shares the award with British biochemist Sir Gregory Winter, PhD. Sometimes called the "Spanish Nobel Prize," the Prince of Asturias Award for Scientific and Technical Research is bestowed for...

2012-05-28 18:20:14

ABBOTT PARK, Ill., May 29, 2012 /PRNewswire/ -- Abbott scientists and independent researchers will highlight the latest investigational research findings on HUMIRA® (adalimumab) at the European League Against Rheumatism (EULAR) Congress in Berlin, Germany, from 6-9 June, 2012. The presentations include two of the longest open-label extension studies in rheumatoid arthritis (RA), featuring long-term data for disease activity and radiographic inhibition. Data will also be presented on...

2012-05-14 02:27:41

PARIS, May 14, 2012 /PRNewswire/ -- - Results of head-to-head study comparing two biologic drugs on a background of methotrexate for the treatment of moderate to severe rheumatoid arthritis to be presented Bristol-Myers Squibb Company [http://www.bms.com ] (NYSE: BMY) today announced that the company will present 18 abstracts on abatacept at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Berlin,...

Advisory Panel Recommends FDA Approval Of Rheumatoid Arthritis Drug
2012-05-11 05:46:04

Connie K. Ho for RedOrbit.com An advisory panel recommends that the U.S. Food and Drug Administration (FDA) consider approving Pfizer´s pill to treat rheumatoid arthritis. The pill, tofacitinib, would be sold to patients who don´t respond to traditional rheumatoid arthritis treatments. On May 9, the panel of outside experts voted 8-2 to recommend the drug for approval. However, the agency doesn´t necessarily need to follow the panel´s advice. Tofacitinib is one of...

2012-04-23 20:20:01

Tokyo, Apr 23, 2012 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they have received notification from Japan's Ministry of Health, Labour and Welfare (MHLW) that the condition for approval of Humira(R) pre-filled syringe 40 mg/0.8 mL for subcutaneous injection (adalimumab [genetical recombination]), a fully human anti-TNF-alpha monoclonal antibody, has been lifted in terms of a drug use results survey (all-case surveillance) for plaque psoriasis and...

2012-04-03 10:06:28

The American College of Rheumatology (ACR) has released the 2012 recommendations for the use of disease-modifying antirheumatic drugs (DMARDs) and biologic agents in the treatment of rheumatoid arthritis (RA). The guidelines published today in the ACR journal, Arthritis Care & Research, are an update to the 2008 recommendations and address the issues of initiating and switching drugs, screening for tuberculosis (TB) reactivation, immunization, and the use of biologics in high-risk RA...